Nuance Biotech, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nuance Biotech, Inc.
Plus deals involving Lilly/Daiichi Sankyo, Humianigen/KPM Tech, Telix/China Grand, Appili/Fujifilm, BioInvent/CASI, Osotec/Adel, Neumentum/Nuance, Takeda/HemoShear and Quantum Genomics/Qilu.
Private Company Edition: I-Mab's $220m Series C round continued the trend of big investments in companies focused on or headquartered in China. Also, Shanghai-based Nuance brought in a combined $35m and European firms dominated recent small financings as US VC deals took a summer break.
China’s Everest licenses global rights to Novartis FGFR4 inhibitor, while Altogen and Lynkogen partner in NASH and metabolic disease.
Sports medicine is the fastest growing specialty in orthopedics, attracting more than 25% of orthopedic residents seeking fellowships for the 2010 training year. Since many sports injuries occur in the young athlete, the way an injury is treated early on may be the determining factor in preventing progressive joint changes and the early onset of degenerative diseases such as osteoarthritis. The promise of new biomaterials and biologics for repairing or replacing supporting soft tissue structures will have a big impact on the orthopedics market for some time to come.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Nuance Biotech (Shanghai) Co. Ltd